Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Deffered Revenue: 2020-2022

Historic Non-Current Deffered Revenue for Candel Therapeutics (CADL) over the last 3 years, with Dec 2022 value amounting to $144,000.

  • Candel Therapeutics' Non-Current Deffered Revenue was N/A to $108,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $108,000, marking a year-over-year change of. This contributed to the annual value of $144,000 for FY2022, which is 83.89% down from last year.
  • Per Candel Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $144,000 for FY2022, which was down 83.89% from $894,000 recorded in FY2021.
  • Candel Therapeutics' 5-year Non-Current Deffered Revenue high stood at $894,000 for FY2021, and its period low was $144,000 during FY2022.
  • In the last 3 years, Candel Therapeutics' Non-Current Deffered Revenue had a median value of $632,000 in 2020 and averaged $556,667.
  • Per our database at Business Quant, Candel Therapeutics' Non-Current Deffered Revenue surged by 41.46% in 2021 and then tumbled by 83.89% in 2022.
  • Yearly analysis of 3 years shows Candel Therapeutics' Non-Current Deffered Revenue stood at $632,000 in 2020, then skyrocketed by 41.46% to $894,000 in 2021, then plummeted by 83.89% to $144,000 in 2022.